UNSPSC 51286202: Fosfomycin calcium

This classification denotes a urinary anti-infective agent C3H5O4P.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 76EIK6888N, chemically known as monocalcium (-)-(1r,2s)-(1,2-epoxypropyl)phosphonate, but more generally known as fosfomycin calcium, which bears US NIH Compound Identifier 93095. European Medicines Agency schedules SUB02261MIGin its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02261MIG. Most nations schedule fosfomycin calcium under HS 29419000 and SITC 54139.

As of Q4 2014, FOSFOMYCIN CALCIUM remains the US FDA Preferred Term for this commodity. SMILES: C[C@H]1[C@H](O1)P(=O)([O-])[O-].[CA+2].

UNSPSC 51286202 Fosfomycin calcium is a Commodity code that nominally designates a single antibiotic pharmaceutical product, but the recent state and local opportunities posted under this code show little alignment with that specific drug. The most substantial recent solicitation—the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products posted January 20, 2026—addresses a broad portfolio of generic drugs and over-the-counter items distributed through authorized wholesalers, not fosfomycin calcium specifically. The other three opportunities on record cover naloxone and drug deactivation systems (Seminole County, Florida, IFB posted June 30, 2026), a Texas HHS Commission request for information on direct-to-manufacturer pharmacy programs (April 3, 2026), and medical and first aid supplies for the Tampa Fire Department (March 25, 2026). None of these represent procurement of fosfomycin calcium as a discrete product line. The code shows activity across state departments, counties, and cities, with repeat participation from large cooperative purchasing vehicles and health agencies, but the opportunities listed do not substantively reflect the code's nominal pharmaceutical scope.

The geographic spread of recent activity spans Minnesota, Texas, and Florida, with the MMCAP procurement extending across multiple states including Oregon. The most decision-relevant recent opportunity is the MMCAP RFP (S1070000015802) due March 26, 2026, which establishes multiple contracts for generic pharmaceuticals and OTC products through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., with contract terms effective July 1, 2026, and price competitiveness weighted at 75 percent of evaluation. The Seminole County naloxone procurement (IFB60459723LAS) was due July 26, 2023, and the City of Tampa medical and first aid supplies solicitation (26P00145) due March 13, 2026, carries an estimated contract value of $700,000.00 and includes a 5 percent bid discount for certified Small Local Business Enterprises. Given the mismatch between the code's nominal drug designation and the actual scope of recent solicitations, this code shows limited relevance for vendors focused specifically on fosfomycin calcium supply.